Search
Sumario de resultados
TIpos de contenido
Fecha
-
NewSafety reporting for clinical investigations under the EU Medical Device Regulation
Safety reporting is a crucial aspect of a successful clinical investigation for medical devices. Which are required to comply with the Medical Devices Regulation (EU) 2017/745 (MDR) and follow the
-
NewBarcelona Science Park sees all-time record in new companies and occupancy
The Barcelona Science Park (PCB), in 2021 and the first two months of 2022, attracted 25 companies, consolidating its place among the most important hubs in Europe in the life sciences and healthcare
-
NewPeaches Biotech Group appoints Alfonso Ortín as new PR Director
The incorporation comes in as the company launches important trials in the area of immunological oncology and regenerative tissue immunology.
-
NewaptaTargets announces first patient dosed in the clinical trial of ApTOLL for COVID-19
The study will evaluate the safety and efficacy of ApTOLL in 30 patients with COVID-19 at four Spanish hospitals
-
NewMerck dona a 47 países de África 1.500 millones de comprimidos para erradicar la esquistos...
Los fármacos donados desde 2007 han llegado a más de 600 millones niños de África subsahariana
-
NewImmunostep presents a renovated product line for basic and clinical research on exosomes
In 2019 Immunostep R&D team recognized the great potential of these small extracellular vesicles and since then they have been working on the development of a line of products for research
-
NewBarcelona based Flomics Biotech closes seed round of €1.000.000 to develop its multicance...
The funds will be used to fuel pre-clinical trials for 5 different types of cancer
-
NewJanssen consolidates its certification as an 'Excellent Family-Responsible Company'
It is a recognition granted by Másfamilia Foundation that recognizes those entities that, from their structure and organization, contribute most to work and family life balance
-
CompanyCeltarys Research
-
NewBCN HEALTH publishes a study evaluating the hospital incidence and medical costs of polycy...
The objective of this study was to evaluate the incidence of the disease at the hospital level and to calculate the associated medical costs
-
NewIntegra Therapeutics closes a new investment of €1.5-million with the addition of Columbus...
The biotechnology firm completes the seed round funding with a total of €6 million led last December by AdBio Partners, Invivo Capital and Takeda Ventures The Integra Therapeutics gene writing
-
NewVenture capital plays key role in fight against cancer
On 28 April, AseBio Investor Day will bring together more than 50 investors from all over the world with disruptive biotech companies so they can meet and consolidate connections. We spoke with some
-
NewORYZON announces appointment of Douglas V. Faller, MD, PhD as Global Chief Medical Officer...
Extensive academic and industry experience in hematology/oncology Will coordinate Oryzon’s global clinical development from Boston, USA
-
-
NewORYZON to give updates on corporate progress in March and April
Virtual Bio-Europe Spring 2022 Kempen Life Sciences Conference Asebio Investor Day
-
NewSpanish clinical research entities start submitting the first clinical trials through CTIS...
Sermes CRO, together with Mikrobiomik, manages the first submission of a clinical trial in Spain through CTIS (Clinical Trial Information System), the new European clinical trial’s portal
-
NewAlgenex Announces Entry into the Food Technology Market
Spanish biotech Algenex announces its expansion into the food tech market. The Company’s patented CrisBio® production platform can deliver the essential biologics that form part of the “growth media”
-
NewAsphalion releases its 2022 CSR plan demonstrating commitment towards UN 2030 sustainable...
Asphalion is enhancing its Corporate Social Responsibility programme with significant commitment to three of UN 2030 sustainable development goals
-
CompanyInnoUp Farma
-
NewConnection shown between glucose metabolism and colorectal tumorigenesis
The results of the study, published in Nature Communications, open up a new path for research to design new, more effective therapeutic targets for this type of tumour, based on blocking the metabolic
-